GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Schott Pharma AG & CO KGaA (XTER:1SXP) » Definitions » Net Income

Schott Pharma AG KGaA (XTER:1SXP) Net Income : €151.8 Mil (TTM As of Sep. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Schott Pharma AG KGaA Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Schott Pharma AG KGaA's Net Income for the six months ended in Sep. 2023 was €151.8 Mil. Its Net Income for the trailing twelve months (TTM) ended in Sep. 2023 was €151.8 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Schott Pharma AG KGaA's Earnings per Share (Diluted) for the six months ended in Sep. 2023 was €1.01.


Schott Pharma AG KGaA Net Income Historical Data

The historical data trend for Schott Pharma AG KGaA's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Schott Pharma AG KGaA Net Income Chart

Schott Pharma AG KGaA Annual Data
Trend Sep20 Sep21 Sep22 Sep23
Net Income
77.48 100.75 125.38 151.84

Schott Pharma AG KGaA Semi-Annual Data
Sep20 Sep21 Sep22 Sep23
Net Income 77.48 100.75 125.38 151.84

Schott Pharma AG KGaA Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Schott Pharma AG KGaA's Net Income for the fiscal year that ended in Sep. 2023 is calculated as

Net Income(A: Sep. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=185.802+-33.868+0+-0.091999999999985
=151.8

Schott Pharma AG KGaA's Net Income for the quarter that ended in Sep. 2023 is calculated as

Net Income(Q: Sep. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=185.802+-33.868+0+-0.091999999999985
=151.8

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Net Income for the trailing twelve months (TTM) ended in Sep. 2023 was €151.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Schott Pharma AG KGaA  (XTER:1SXP) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Schott Pharma AG KGaA's Earnings per Share (Diluted) (EPS) for the quarter that ended in Sep. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Schott Pharma AG KGaA Net Income Related Terms

Thank you for viewing the detailed overview of Schott Pharma AG KGaA's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Schott Pharma AG KGaA (XTER:1SXP) Business Description

Traded in Other Exchanges
Address
Hattenbergstraße 10, Mainz, DEU, 55122
Schott Pharma AG & CO KGaA is a multinational glass company specializing in the manufacture of glass and glass ceramics. It is represented in 34 countries and serves a multitude of industries from Healthcare, Home Appliances and living, and Consumer Electronics to Semiconductors and datacom, Optics, Industry and energy, Automotive, and Astronomy and aerospace.
Executives
Andreas Reisse Board of Directors
Ann-kristin Erkens Supervisory Board
Dr. Almuth Steinkühler Board of Directors
Dr. Jens Schulte Supervisory Board
Dr. Wolfgang Wienand Supervisory Board
Peter Goldschmidt Supervisory Board

Schott Pharma AG KGaA (XTER:1SXP) Headlines

No Headlines